All In Biotech

Drug Trial Radar · NCT03735979

Multi-arm Optimization of Stroke Thrombolysis

Multi-arm Optimization of Stroke Thrombolysis (MOST): a Single Blinded, Randomized Controlled Adaptive, Multi-arm, Adjunctive-thrombolysis Efficacy Trial in Ischemic Stroke

Last checked: Nov 20, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 514 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

514

Actual

Start

Oct 15, 2019

Primary completion

Dec 1, 2023

Study completion Oct 31, 2024

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
First posted
Nov 8, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results in improved 90-day modified Rankin scores (mRS) as compared with placebo in acute ischemic stroke (AIS) patients treated with standard of care thrombolysis (0.9mg/kg IV rt-PA or 0.25mg/kg IV tenecteplase or TNK) within three hours of symptom onset. Patients may also receive endovascular thrombectomy (ET) per usual care. Time of onset is defined as the last time the patient was last known to be well.

Conditions

  • Acute Ischemic Stroke

Interventions

  • ArgatrobanDrug

    Direct Thrombin Inhibitor - Argatroban is a derivative of arginine that competitively binds to the active site of thrombin thereby preventing fibrin deposition. With a half-life of 30 minutes, argatroban has an immediate anticoagulant effect after IV administration which is rapidly reversed with discontinuation of the drug.

  • EptifibatideDrug

    GP 2b/3a Receptor Inhibitor - The final step of platelet aggregation is mediated via the GP2b/3a receptor. Eptifibatide was specifically developed to ensure rapid inhibition of platelet aggregation (within 15 minutes), a short half-life (\~2 hours) and rapid dissociation from platelets with 50% restoration of platelet function within 2-4 hours of discontinuation.

  • PlaceboDrug

    IV placebo solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 90-day Utility Weighted Modified Rankin Scores (UW-mRS)Time frame: 90 days after randomization

Locations

61 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama Hospital

    Birmingham, Alabama

  • St. Jude Medical Center

    Fullerton, California

  • UCSD Health La Jolla

    La Jolla, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • UC Irvine Medical Center

    Orange, California

  • UCSD Medical Center - Hillcrest Hospital

    San Diego, California

  • San Francisco General Hospital

    San Francisco, California

  • UCSF Medical Center

    San Francisco, California

  • Santa Barbara Cottage Hospital

    Santa Barbara, California

  • Yale New Haven Hospital

    New Haven, Connecticut

  • Baptist Medical Center Jacksonville

    Jacksonville, Florida

  • Mayo Clinic Hospital

    Jacksonville, Florida

  • Jackson Memorial Hospital

    Miami, Florida

  • Sarasota Memorial Hospital

    Sarasota, Florida

  • Tampa General Hospital

    Tampa, Florida

  • Grady Memorial Hospital

    Atlanta, Georgia

  • University of Chicago Medical Center

    Chicago, Illinois

  • Loyola University Medical Center

    Maywood, Illinois

  • Javon Bea Hospital - Riverside

    Rockford, Illinois

  • Central DuPage Hospital

    Winfield, Illinois

  • University of Kansas Hospital

    Kansas City, Kansas

  • University of Kentucky Hospital

    Lexington, Kentucky

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • UMASS Memorial Medical Center

    Worcester, Massachusetts

  • University of Michigan University Hospital

    Ann Arbor, Michigan

  • Henry Ford Hospital

    Detroit, Michigan

  • McLaren Flint

    Flint, Michigan

  • Trinity Health Saint Mary's

    Grand Rapids, Michigan

  • Fairview Southdale Hospital

    Edina, Minnesota

  • University of Minnesota Medical Center Hospital

    Minneapolis, Minnesota

  • Regions Hospital

    Saint Paul, Minnesota

  • Saint Luke's Hospital

    Kansas City, Missouri

  • St. Louis University Hospital

    St Louis, Missouri

  • Barnes Jewish Hospital

    St Louis, Missouri

  • University of New Mexico Hospital

    Albuquerque, New Mexico

  • North Shore University Hospital

    Manhasset, New York

  • Mount Sinai Beth Israel

    New York, New York

  • SUNY Upstate University Hospital

    Syracuse, New York

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.